Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director · See Remarks | August 24, 2026 | August 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date August 24, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 488,182 |
Reported balance
After 2026-08-24 transaction · row 1
1 source rowRow 1 · 2026-08-24 · Sale · Disposed 13,818 · Balance 488,182 F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2: This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F2: This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2021 Filed May 5, 2021 21:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 24,080 | $1.07 | $25,765.60 |
DisclosureSEC source: 0001209191-21-030393 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 41,666 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001209191-21-024705 · doc4.xml · derivative · entry 9 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,032 Underlying: Class A Common Stock · 41,666 shares Expires 2026-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $186.08 | $55,823.49 |
DisclosureSEC source: 0001209191-21-024705 · doc4.xml · nonDerivative · entry 8 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,636 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $186.005 to $186.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 14,632 | $185.52 | $2,714,562.29 |
DisclosureSEC source: 0001209191-21-024705 · doc4.xml · nonDerivative · entry 7 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,936 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $185.02 to $185.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 16,748 | $184.53 | $3,090,521.84 |
DisclosureSEC source: 0001209191-21-024705 · doc4.xml · nonDerivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,568 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $184.02 to $185.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,686 | $183.74 | $1,228,511.05 |
DisclosureSEC source: 0001209191-21-024705 · doc4.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,316 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $183.02 to $184.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,900 | $182.48 | $346,703.07 |
DisclosureSEC source: 0001209191-21-024705 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,002 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $181.96 to $182.90. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $181.50 | $108,900.00 |
DisclosureSEC source: 0001209191-21-024705 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,902 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $180.96 to $181.91. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800 | $179.98 | $143,986.00 |
DisclosureSEC source: 0001209191-21-024705 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,502 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $179.80 to $180.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 21:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 41,666 | $1.07 | $44,582.62 |
DisclosureSEC source: 0001209191-21-024705 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| March 19, 2021 Filed May 27, 2021 00:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 27,922 | $0.00 Strike: $177.76 | $0.00 |
DisclosureSEC source: 0001209191-21-036101 · doc4.xml · derivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,922 Underlying: Class A Common Stock · 27,922 shares Expires 2031-03-19 F5 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2021 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 19, 2021 Filed May 27, 2021 00:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 11,169 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036101 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,805 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-sixteenth of the RSUs shall vest on May 21, 2021 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. F2 · balance_after: The number of shares beneficially owned following the reported transaction is as of March 19, 2021. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 5,302 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001209191-21-020874 · doc4.xml · derivative · entry 10 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,698 Underlying: Class A Common Stock · 5,302 shares Expires 2026-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · derivative.exercise_date: This option, originally for 125,000 shares, of which 5,302 shares have been exercised, vested as to one-fourth of the shares on August 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 36,364 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-21-020874 · doc4.xml · derivative · entry 9 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 36,364 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 7,167 | $159.40 | $1,142,386.12 |
DisclosureSEC source: 0001209191-21-020874 · doc4.xml · nonDerivative · entry 8 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,636 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $159.03 to $159.97. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,368 | $158.64 | $1,010,222.70 |
DisclosureSEC source: 0001209191-21-020874 · doc4.xml · nonDerivative · entry 7 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,803 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $158.02 to $159.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,845 | $157.48 | $920,451.90 |
DisclosureSEC source: 0001209191-21-020874 · doc4.xml · nonDerivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,171 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $157.02 to $158.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 8,189 | $156.45 | $1,281,142.85 |
DisclosureSEC source: 0001209191-21-020874 · doc4.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,016 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $156.005 to $156.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 8,074 | $155.54 | $1,255,814.62 |
DisclosureSEC source: 0001209191-21-020874 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,205 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $155.01 to $156.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,023 | $154.56 | $930,887.17 |
DisclosureSEC source: 0001209191-21-020874 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,279 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $154.00 to $154.985. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 5,302 | $1.07 | $5,673.14 |
DisclosureSEC source: 0001209191-21-020874 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 36,364 | $0.88 | $32,000.32 |
DisclosureSEC source: 0001209191-21-020874 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 607 | $179.01 | $108,661.86 |
DisclosureSEC source: 0001209191-21-007559 · doc4.xml · nonDerivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,636 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $178.86 to $179.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,998 | $177.68 | $532,671.45 |
DisclosureSEC source: 0001209191-21-007559 · doc4.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,243 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $177.36 to $178.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,322 | $176.65 | $1,116,780.67 |
DisclosureSEC source: 0001209191-21-007559 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,241 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $176.25 to $177.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 18,374 | $175.74 | $3,229,090.86 |
DisclosureSEC source: 0001209191-21-007559 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,563 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $175.25 to $176.23. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,749 | $174.90 | $830,601.05 |
DisclosureSEC source: 0001209191-21-007559 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,937 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $174.24 to $175.23. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 700 | $173.79 | $121,649.99 |
DisclosureSEC source: 0001209191-21-007559 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,686 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $173.21 to $174.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,200 | $141.58 | $169,896.48 |
DisclosureSEC source: 0001209191-21-002190 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,386 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $141.315 to $142.07. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,825 | $140.62 | $959,744.47 |
DisclosureSEC source: 0001209191-21-002190 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,586 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $140.28 to $141.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 22,026 | $139.83 | $3,079,814.08 |
DisclosureSEC source: 0001209191-21-002190 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,411 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $139.27 to $140.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,699 | $138.78 | $513,345.74 |
DisclosureSEC source: 0001209191-21-002190 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,437 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $138.265 to $139.19. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 23:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-20-065242 · doc4.xml · derivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,000 Underlying: Class A Common Stock · 28,000 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, originally for 200,000 shares, of which 28,000 shares have been exercised, vested as to one forty-eighth of the shares on October 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 23:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 8,636 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-20-065242 · doc4.xml · derivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,364 Underlying: Class A Common Stock · 8,636 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 23:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 28,000 | $1.20 | $33,600.00 |
DisclosureSEC source: 0001209191-20-065242 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 23:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 8,636 | $0.88 | $7,599.68 |
DisclosureSEC source: 0001209191-20-065242 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 33,750 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-20-061712 · doc4.xml · derivative · entry 7 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A Common Stock · 33,750 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,835 | $153.68 | $435,682.23 |
DisclosureSEC source: 0001209191-20-061712 · doc4.xml · nonDerivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $153.45 to $154.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,700 | $153.14 | $719,771.63 |
DisclosureSEC source: 0001209191-20-061712 · doc4.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,335 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $152.44 to $153.42. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,619 | $151.84 | $701,333.72 |
DisclosureSEC source: 0001209191-20-061712 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,035 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $151.41 to $152.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 11,113 | $150.92 | $1,677,222.86 |
DisclosureSEC source: 0001209191-20-061712 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,654 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $150.41 to $151.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 10,483 | $150.07 | $1,573,137.68 |
DisclosureSEC source: 0001209191-20-061712 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,767 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $149.41 to $150.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 33,750 | $0.88 | $29,700.00 |
DisclosureSEC source: 0001209191-20-061712 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 02:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 12,688 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-20-057067 · doc4.xml · derivative · entry 13 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 Underlying: Class A Common Stock · 12,688 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F11 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 02:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 295 | $138.49 | $40,854.90 |
DisclosureSEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 11 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · price: This transaction was executed in multiple trades at prices ranging from $138.20 to $138.66. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 02:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 7,353 | $137.57 | $1,011,559.56 |
DisclosureSEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 10 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,795 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $137.11 to $138.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 02:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,642 | $136.62 | $634,209.54 |
DisclosureSEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 9 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,148 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $136.09 to $137.07. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 02:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 398 | $135.52 | $53,935.97 |
DisclosureSEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 8 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,790 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $135.07 to $135.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 02:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 12,688 | $0.88 | $11,165.44 |
DisclosureSEC source: 0001209191-20-057067 · doc4.xml · nonDerivative · entry 7 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 02:34 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 21,062 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-20-057067 · doc4.xml · derivative · entry 12 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,438 Underlying: Class A Common Stock · 21,062 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F11 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.